Sat, Apr 19, 2014, 1:38 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Nymox Pharmaceutical Corporation Message Board

  • ckbenergy ckbenergy Mar 26, 2007 9:08 AM Flag

    P value - ALXA

    The Phase IIa clinical trial was designed as a multi-center, randomized, double-blind, placebo-controlled study of 120 patients in an in-patient clinical setting. In the trial, two doses of AZ-004 (Staccato loxapine in 5 and 10 mg doses) and placebo (Staccato device containing no drug) were tested. The primary aim of the clinical trial was to assess the safety and efficacy of a single dose of AZ-004 in acutely treating agitation in schizophrenic patients. Assessments of a patient's agitation state were conducted at serial time points using both standard agitation scales and objective measures of patient's movement over a 4-hour period, with follow-up assessments for the next 20 hours. The change in the PANSS (Positive and Negative Symptom Scale) Excited Component (PEC) score at the 2-hour post-dose time point was the primary efficacy measure for the clinical study. All results were considered statistically significant at the p < 0.05 level and all analyses were made on an intent-to-treat basis. Side effects were recorded throughout the clinical trial study period.

    ALXA just hit 15 this morning atfer a successful phase 2.

    The shorts could wake up any morning and see double digits.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.0401-0.2199(-4.18%)Apr 17 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.